---
schema_version: "secwatch.filing_event.v1"
accession: "0001567264-25-000011"
form_type: "8-K"
ticker: "INTS"
cik: "0001567264"
company_name: "INTENSITY THERAPEUTICS, INC."
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T21:14:52.603017+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Intensity Therapeutics reports 2024 net loss of $16.3M; cash $2.6M; trial enrollment ongoing

## Summary
- Net loss of $16.3M for FY2024 vs $10.5M in 2023; R&D expenses rose to $10.5M from $4.8M.
- Cash and cash equivalents total $2.6M as of December 31, 2024.
- INVINCIBLE-3 (Phase 3 sarcoma) has 32 sites contracted, 25 patients screened; enrollment expected by first half 2026.
- INVINCIBLE-4 (Phase 2 TNBC) has 8 Swiss sites activated, several patients treated; enrollment expected end Q1 2026.

## SEC filing metadata
- accession: 0001567264-25-000011
- form_type: 8-K
- ticker: INTS
- cik: 0001567264
- company_name: INTENSITY THERAPEUTICS, INC.
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567264/000156726425000011/0001567264-25-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567264/000156726425000011/intensity-20250313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001567264-25-000011
- JSON: https://secwatch.observer/filing/0001567264-25-000011.json
- Plain text: https://secwatch.observer/filing/0001567264-25-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.